Travere Therapeutics, Inc. (TVTX): EV/EBITDA Multiple

Travere Therapeutics (TVTX) stock volatility is driven by its dependence on the success of Filspari and associated regulatory risks. However, the sale of patented orphan drugs for rare kidney pathologies via insurance, coupled with high physician loyalty, provides stability. The EV/EBITDA ratio of this capital-intensive business demonstrates the market value of a leveraged asset, while the 151.21 mark reflects the latest multiplier data.
TVTX (Retrophin): analytical breakdowns and indicator data

This indicator compares the total enterprise value, including net debt, with its operating profit before depreciation and amortization, allowing for an assessment of the real value of assets relative to the generated cash flow. By analyzing the current EV/EBITDA trend of Travere Therapeutics (TVTX), an investor determines the balance between stock undervaluation and the risks of declining revenues from the sale of innovative drugs for the treatment of rare kidney pathologies.